Feb 2016 $5 M No. 5 $2 to $10 million 1
Alexza Pharmaceuticals Inc.: Raise no. 5, Feb 2016 × Investors in this round 1 investor had bought by the notice of Feb 24, 2016: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Edwin S Kamemoto · Executive Officer Thomas B King · Executive Officer, Director Deepika R Pakianathan · Director Gordon Leighton Ringold · Director Isaac Leighton Stein · Director J Kevin Buchi · Director J Leighton Read · Director Joseph L Turner · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Shares issued in consideration of reduction in outstanding balance of a note dated 5/07/13 by $5,000,000 and forgiveness of accrued and unpaid interest thereunder as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on 2/24/2016”Signed by Thomas B. King, Pres & CEO. Source: SEC Form D, newest notice filed Feb 24, 2016. Read the notice at the SEC .
equity SEC Oct 2014 $8 M No. 4 $2 to $10 million 1
Alexza Pharmaceuticals Inc.: Raise no. 4, Oct 2014 × Investors in this round 1 investor had bought by the notice of Oct 28, 2014: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Edwin S Kamemoto · Executive Officer James V Cassella · Executive Officer Mark K Oki · Executive Officer Robert A Lippe · Executive Officer Thomas B King · Executive Officer, Director Deepika R Pakianathan · Director Gordon Leighton Ringold · Director Isaac Leighton Stein · Director J Kevin Buchi · Director J Leighton Read · Director Joseph L Turner · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Thomas B. King, Pres & CEO. Source: SEC Form D, newest notice filed Oct 28, 2014. Read the notice at the SEC .
equity SEC Mar 2012 $3 M No. 3 $2 to $10 million 1
Alexza Pharmaceuticals Inc.: Raise no. 3, Mar 2012 × Investors in this round 1 investor had bought by the notice of Mar 16, 2012: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice James V Cassella · Executive Officer Mark K Oki · Executive Officer Michael J Simms · Executive Officer Thomas B King · Executive Officer, Director Andrew L Busser · Director Deepika R Pakianathan · Director Gordon Leighton Ringold · Director Hal V Barron · Director Isaac Leighton Stein · Director J Leighton Read · Director Joseph L Turner · Director Samuel D. Colella · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Thomas B King, President & Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 16, 2012. Read the notice at the SEC .
equity SEC May 2010 $1 M No. 2 Under $2 million 1
Alexza Pharmaceuticals Inc.: Raise no. 2, May 2010 × Investors in this round 1 investor had bought by the notice of May 12, 2010: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice August J Moretti · Executive Officer James V Cassella · Executive Officer Michael J Simms · Executive Officer Thomas B King · Executive Officer, Director Alan D Frazier · Director Andrew L Busser · Director Deepika R Pakianathan · Director Gordon Leighton Ringold · Director Hal V Barron · Director Isaac Leighton Stein · Director J Leighton Read · Director Samuel D Colella · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Thomas B King, President & Chief Executive Officer. Source: SEC Form D, newest notice filed May 12, 2010. Read the notice at the SEC .
options SEC Oct 2009 $20 M No. 1 $10 to $50 million 30
Alexza Pharmaceuticals Inc.: Raise no. 1, Oct 2009 × Investors in this round 30 investors had bought by the notice of Oct 6, 2009: 30 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $20 M of $20 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $551,028
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice August J Moretti · Executive Officer James V Cassella · Executive Officer Michael J Simms · Executive Officer Thomas B King · Executive Officer, Director Alan D Frazier · Director Andrew L Busser · Director Deepika R Pakianathan · Director Gordon Leighton Ringold · Director Hal V Barron · Director Isaac Leighton Stein · Director J Leighton Read · Director Samuel D Colella · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round RBC Capital Markets Corporation (CRD 31194) · broker-dealer RBC Capital Markets Corporation (CRD 31194) · San Francisco, Ca Sold in no state named Signed by Thomas B King, President & Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 6, 2009. Read the notice at the SEC .
equity, options SEC